Perioperative locoregional application of mitoxantrone in patients with early breast carcinoma

被引:4
作者
Baitchev, G [1 ]
Gorchev, G [1 ]
Deliisky, T [1 ]
Popovska, S [1 ]
Raitcheva, T [1 ]
机构
[1] Higher Med Inst, Ctr Oncol, Dept Surg, Pleven 5800, Bulgaria
关键词
breast cancer; early breast cancer; mitoxantrone; axillary lymph nodes; locoregional drug dosage;
D O I
10.1179/joc.2001.13.4.440
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this study was to investigate the clinical and morphological aspects of drug diffusion and efficacy after perioperative locoregional application of mitoxantrone in patients with early breast cancer. Mitoxantrone was injected at a dose of 0.5 ml (1.0 mg) in two sites around the tumor in 37 patients. Intraoperative inspection of mitoxantrone diffusion in breast and axillary tissues was carried out by blue color of the chemotherapeutic drug. Investigations of reactive morphological changes in axillary nodes were determined intraoperatively by blue stained lymph capillaries identified 2-4 cm laterally from the application sites and in 30 patients a mean of 1.5 stained axillary nodes was found. The light microscopy in the metastatic blue lymph nodes showed circulatory changes, dilatation of marginal sinus and inflammatory alterations. It was concluded that lymphotropic locoregional application of mitoxantrone results in diffusion of the drug in the regional lymph drainage and in cytotoxic effects on axillary nodes.
引用
收藏
页码:440 / 443
页数:4
相关论文
共 9 条
[1]  
DORR RT, 1986, CANCER CHEMOTH PHARM, V16, P91
[2]  
DUNN CJ, 1996, DRUGS AGENTS, V9, P123
[3]  
EHNINGER G, 1986, CANCER TREAT REP, V70, P1373
[4]  
LENK H, 1987, ANTICANCER RES, V7, P1257
[5]   MORPHOLOGICAL EFFECTS OF MITOXANTRONE AND A RELATED ANTHRACENEDIONE ON LYMPHOID-TISSUES [J].
LEVINE, S ;
GHERSON, J .
INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 1986, 8 (08) :999-&
[6]  
MARKMAN M, 1996, J RES CLIN ONCOL, V12, P1
[7]  
MURANISHI S, 1991, ADV DRUG RES, V21, P2
[8]  
NAGEL JD, 1997, REG CANC TREAT S, V1, P39
[9]  
STEWART DJ, 1986, CANCER TREAT REP, V70, P1255